Sanctuary Advisors LLC Purchases 631 Shares of Vericel Co. (NASDAQ:VCEL)

Sanctuary Advisors LLC lifted its position in Vericel Co. (NASDAQ:VCEL) by 14.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 5,013 shares of the biotechnology company’s stock after purchasing an additional 631 shares during the quarter. Sanctuary Advisors LLC’s holdings in Vericel were worth $297,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC grew its holdings in Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 619 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Vericel by 48.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 405 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Vericel by 22.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 322 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in Vericel during the 3rd quarter worth about $92,000. Finally, Geneos Wealth Management Inc. grew its holdings in Vericel by 826.6% during the 4th quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock worth $138,000 after acquiring an additional 2,240 shares during the last quarter.

Insider Activity at Vericel

In related news, Director Robert L. Md Zerbe sold 2,500 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the completion of the sale, the director now directly owns 26,595 shares of the company’s stock, valued at approximately $1,662,187.50. This represents a 8.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jonathan Siegal sold 3,908 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $61.99, for a total value of $242,256.92. Following the sale, the insider now directly owns 1,206 shares of the company’s stock, valued at approximately $74,759.94. The trade was a 76.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 7,500 shares of company stock worth $466,200 in the last ninety days. Company insiders own 5.20% of the company’s stock.

Vericel Price Performance

Shares of NASDAQ:VCEL opened at $51.14 on Wednesday. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of 852.48 and a beta of 1.72. The firm’s 50 day simple moving average is $56.93 and its 200 day simple moving average is $51.93. Vericel Co. has a fifty-two week low of $39.12 and a fifty-two week high of $63.00.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on VCEL shares. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Vericel in a research report on Friday, February 28th. Canaccord Genuity Group upped their target price on shares of Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. StockNews.com downgraded shares of Vericel from a “hold” rating to a “sell” rating in a research report on Friday, February 28th. Stephens restated an “overweight” rating and set a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. Finally, BTIG Research upped their target price on shares of Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Vericel presently has a consensus rating of “Moderate Buy” and an average target price of $62.29.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.